Value
7.8/10data confidence 60%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 6.7 |
| EV/EBITDA | 6.8 |
- ▸Attractively valued
QTTB · Why this verdict
Why Q32 Bio (QTTB) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Q32 Bio combines exceptional fundamental quality, a perfect earnings-beat streak, and roughly 133% modeled upside to its analyst target with momentum sitting right at the engine's pass/fail gate and a short-squeeze setup the engine still flags as needing validation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Q32 Bio shows excellent fundamentals -- a 72% ROE, 63% margins, a wide economic moat, and a perfect Piotroski F-Score of 9 out of 9 -- earning the engine's high-quality-business and compounder-quality flags. Quality breakdown | The Piotroski F-Score should hold at 8 or 9 out of 9 and ROE should stay above 50% over the next several quarters. | →Stable |
| CounterClinical-stage or early-commercial biotech names can show misleadingly strong margin and ROE readings from licensing or milestone payments that don't recur, so these metrics could reverse sharply once one-time items roll off. | ||
The engine estimates roughly 133% upside to the analyst price target for Q32 Bio, based on the current v9 upside read of 132.9%. Estimated upside | The stock should close a meaningful portion of the gap to the analyst target -- at least 30 percentage points of the current 133% upside -- over the next 12 months. | →Stable |
| CounterBiotech names flagged as a binary industry can see analyst targets swing wildly around single trial readouts, so a large modeled upside can evaporate instantly on a negative data event rather than closing gradually. | ||
Momentum sits exactly at the engine's hard gate of 4.5, the minimum to pass, but remains below the softer 5.5 watch threshold, and the buy-confidence check flags this specific momentum reading as unresolved and needing validation. Buy confidence reasons | The momentum score should climb clearly above the 5.5 soft threshold, resolving the needs-validation flag. | →Stable |
| CounterRising on-balance volume is a genuine positive signal, but momentum sitting exactly at a pass/fail boundary is inherently fragile and could fail the gate on the very next data refresh. | ||
The company has beaten consensus EPS in all four of its last reported quarters, with an average surprise of roughly 180%. Catalyst breakdown | The beat streak should extend to at least 5 consecutive quarters. | ↓Deteriorating |
| CounterA 180% average surprise on a pre-revenue or early-revenue biotech is often driven by estimate-vs-actual noise on tiny loss-per-share bases rather than a repeatable operating trend, and any single miss would break the streak the market has come to expect. | ||
The engine flags a short-squeeze setup -- 15% short interest against a 7.5 quality read -- alongside an elevated put/call ratio of 17.08 and implied volatility near 106%. Risk breakdown | Short interest should decline from 15% as positioning unwinds, or a squeeze should materialize with a sharp upward price move. | ↓Deteriorating |
| CounterA put/call ratio this extreme more plausibly reflects thin, illiquid options volume than genuine broad-based hedging or shorting pressure, so the short-squeeze-setup read could be a data artifact rather than a real catalyst. | ||
Q32 Bio shows excellent fundamentals -- a 72% ROE, 63% margins, a wide economic moat, and a perfect Piotroski F-Score of 9 out of 9 -- earning the engine's high-quality-business and compounder-quality flags.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should hold at 8 or 9 out of 9 and ROE should stay above 50% over the next several quarters.
CounterClinical-stage or early-commercial biotech names can show misleadingly strong margin and ROE readings from licensing or milestone payments that don't recur, so these metrics could reverse sharply once one-time items roll off.
The engine estimates roughly 133% upside to the analyst price target for Q32 Bio, based on the current v9 upside read of 132.9%.
→StableEstimated upside
- Expectation
- The stock should close a meaningful portion of the gap to the analyst target -- at least 30 percentage points of the current 133% upside -- over the next 12 months.
CounterBiotech names flagged as a binary industry can see analyst targets swing wildly around single trial readouts, so a large modeled upside can evaporate instantly on a negative data event rather than closing gradually.
Momentum sits exactly at the engine's hard gate of 4.5, the minimum to pass, but remains below the softer 5.5 watch threshold, and the buy-confidence check flags this specific momentum reading as unresolved and needing validation.
→StableBuy confidence reasons
- Expectation
- The momentum score should climb clearly above the 5.5 soft threshold, resolving the needs-validation flag.
CounterRising on-balance volume is a genuine positive signal, but momentum sitting exactly at a pass/fail boundary is inherently fragile and could fail the gate on the very next data refresh.
The company has beaten consensus EPS in all four of its last reported quarters, with an average surprise of roughly 180%.
↓DeterioratingCatalyst breakdown
- Expectation
- The beat streak should extend to at least 5 consecutive quarters.
CounterA 180% average surprise on a pre-revenue or early-revenue biotech is often driven by estimate-vs-actual noise on tiny loss-per-share bases rather than a repeatable operating trend, and any single miss would break the streak the market has come to expect.
The engine flags a short-squeeze setup -- 15% short interest against a 7.5 quality read -- alongside an elevated put/call ratio of 17.08 and implied volatility near 106%.
↓DeterioratingRisk breakdown
- Expectation
- Short interest should decline from 15% as positioning unwinds, or a squeeze should materialize with a sharp upward price move.
CounterA put/call ratio this extreme more plausibly reflects thin, illiquid options volume than genuine broad-based hedging or shorting pressure, so the short-squeeze-setup read could be a data artifact rather than a real catalyst.
Per-dimension breakdown
Quality
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 9.8 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 4.5 |
| Moat | 8.0 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 72%
- ▸Strong margins: 63%
- ▸Earnings quality warning: 57% FCF/NI
- ▸Wide economic moat
Growth
5.0/10data confidence 50%Momentum
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 1.8 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 10.0 |
| vol acceleration | 1.0 |
- ▸Capitulation risk (RSI 28, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+20.2%/30d) — pullback in uptrend, not confirmed weakness
- ▸Volume surge (5.4x avg) on selloff
Sentiment
8.9/10data confidence 100%| Component | Sub-score |
|---|---|
| news sentiment | 10.0 |
| Analyst rating | 7.3 |
| Price target | 10.0 |
- ▸Positive news sentiment (+1.00)
- ▸Light analyst coverage (5.0) — signal dampened
- ▸Analyst upside: 379%
Insider
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider selling — $275,144 (0.097% of mkt cap)
- ▸Institutions accumulating
Peer rank
7.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.1 |
| quality rank | 9.5 |
| growth rank | 5.0 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.5 |
| support resistance | 9.4 |
| 52w position | 0.0 |
| gap | 3.0 |
- ▸Extreme gap up (9.1%) - may pull back
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.9 |
| days to cover | 3.5 |
| volatility | 0.0 |
| put call | 0.3 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| debt equity | 9.8 |
| news risk | 6.0 |
- ▸Short squeeze setup: 18% short, quality 7.5
- ▸Elevated put/call: 1.96
- ▸High IV: 116%
Catalyst
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Market cap $284M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.2<4.5
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupOversold Bounce — Oversold RSI 28, near Bollinger lower, volume surge
EdgeTemporary headwind — High quality (8.2) with weak momentum (3.2)
SuitabilitySpeculative — Drawdown -65% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 3.2<4.5 outcome against Sentiment at 8.9 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 8.9, Quality at 8.2, and Value at 7.8; the weakest are Momentum at 3.2, Risk (lower is worse) at 4.3, and Growth at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1High Quality Compounder Fundamentals
Trip ifPiotroski F-Score falls below 6 out of 9 from the current 9, or ROE falls below 30% from the current 72%.
- P2Large Upside To Analyst Target
Trip ifUpside_pct falls below 30% from the current 132.9%, closing most of the gap to the analyst target.
- P3Momentum Right At The Gate Threshold
Trip ifMomentum score falls below 4.5, causing the stock to fail the engine's hard momentum gate outright.
- P4Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% in the next reported quarter, breaking the current 4-quarter beat streak.
- P5Short Squeeze Setup With Elevated Hedging
Trip ifShort interest falls below 5% from the current 15%, unwinding the short-squeeze setup without a corresponding price spike.